Astrazeneca
Anglo-Swedish pharma major with a deep oncology and respiratory pipeline.
Coverage of Astrazeneca is holding steady : 6 signals on the latest tracked day, up 50% from its three-week baseline of 4, across 4 domains (up from 2 a week ago). That makes it the #309 most-covered of the 348 concerns we track.
What’s changed
5 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.
- STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and more · STAT News — All Content · 2026-08-28
- STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs · STAT News — All Content · 2026-08-28
- STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching · STAT News — All Content · 2026-08-28
- AstraZeneca, CSPC to form joint venture for biologics manufacturing · Fierce Pharma · 2026-08-05
- ESC: AZ, Ionis' Wainua post-mortem throws water on silencer-plus-stabilizer approach in ATTR-CM · Fierce Pharma · 2026-08-30
- Untitled Letters · FDA — What's New: Drugs · 2026-08-28
What the reporting says
Across 38 tracked stories from 12 outlets, reporting on Astrazeneca most often describes regulatory approvals (3), public statements (2), IPOs or listings (1), military action (1), legal rulings (1), sanctions or trade (1).
It shows up alongside Bristol Myers Squibb (14), Merck (9), FDA (12), Lung Cancer (10), Abstract (9), China (9), Immunotherapy (8).
Two steps out: AI (through FDA, 12 shared stories on the weaker link); Cder (through FDA, 12 shared stories on the weaker link); Clinical Trials (through FDA, 12 shared stories on the weaker link); Colorectal Cancer (through FDA, 12 shared stories on the weaker link).
Tracked since May 5, with coverage on 24 separate days — concentrated in Preprint and FDA Decisions.